Loading data for DNA — first visit, this takes a few seconds.
Ginkgo Bioworks Inc. (DNA)
NYSE: DNA
· Real-Time Price · USD
7.40
+0.44 (6.32%)
At close: Aug 21, 2026, 3:59 PM
7.47
+0.95%
After-hours: 7:48 PM
The price, the headline numbers and the latest news, in one place.
Ginkgo Bioworks Inc. (DNA) Stock Price, Analysis & Data
6.32% (1D)
| Bid | 7.24 |
| Market Cap | 498.32M |
| Revenue (ttm) | 132.42M |
| Net Income (ttm) | -309.64M |
| 1.79 | |
| -5.33 | |
| n/a | |
| -2.55 | |
| P/B (ttm) | 1.12 |
| P/S (ttm) | 3.76 |
| Earnings Date | n/a |
| Ask | 7.4 |
| Volume | 1,325,040 |
| Avg. Volume (20D) | 1,189,683 |
| Open | 7.09 |
| Previous Close | 6.96 |
| Day's Range | 6.82 - 7.42 |
| 52-Week Range | 5.37 - 17.58 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automat...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 19, 2021
Employees 485
Stock Exchange NYSE
Ticker Symbol DNA
Website https://www.ginkgo.bio
Financial Performance
In 2025, Ginkgo Bioworks's revenue was 170.16M, a decrease of -25.06% compared to the previous year's 227.04M. Earnings were -312.76M, a decrease of -42.83%.
Financial Statements
